Cancer Treatment Reviews
Volume 30, Issue 7 , Pages 655-659, November 2004

Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer:☆☆☆☆

Abstracted from: Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2. J Clin Oncol 2004;22:785–94.

Cancer Care Ontario, c/o 620 University Avenue, Toronto, Ontario M5G 2L7, Canada

published online 25 October 2004.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Sources of funding: This study was funded by Astra Zeneca, Wilmington, Delaware, USA.

☆ For Correspondence: Roy Herbst, Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Holcombe Blvd, Houston, TX, USA. E-mail: rherbst@mail.mdanderson.org

☆☆ Abstract provided by Bazian Ltd, London.

PII: S0305-7372(04)00144-6

doi:10.1016/j.ctrv.2004.08.002

Cancer Treatment Reviews
Volume 30, Issue 7 , Pages 655-659, November 2004

Article Tools